Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 8/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1566802 | 1.00 | DHODH (0.50) | DHODHMAPTMAPK1CYP1A2CYP3A4 | |
| SCHEMBL8246811 | 1.00 | DHODH (0.50) | DHODHMAPTMAPK1CYP1A2CYP3A4 | |
| SCHEMBL8246814 | 0.90 | GAA (0.54) | DHODHMAPTMAPK1CYP1A2CYP3A4 | |
| SCHEMBL7157266 | 0.85 | KMT2A (0.52) | DHODHMAPTMAPK1CYP1A2CYP3A4 | |
| SCHEMBL7157263 | 0.85 | KMT2A (0.52) | DHODHMAPTMAPK1CYP1A2CYP3A4 | |
| SCHEMBL7157291 | 0.85 | MAPT (0.57) | DHODHMAPTMAPK1CYP1A2CYP3A4 | |
| SCHEMBL7157293 | 0.85 | MAPT (0.57) | DHODHMAPTMAPK1CYP1A2CYP3A4 | |
| SCHEMBL7158653 | 0.84 | MAPT (0.53) | DHODHMAPTMAPK1CYP1A2CYP3A4 | |
| SCHEMBL7158657 | 0.84 | MAPT (0.53) | DHODHMAPTMAPK1CYP1A2CYP3A4 | |
| SCHEMBL7153389 | 0.82 | DHODH (0.51) | DHODHMAPTMAPK1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119509-A1 | Altenrative Forms Of The Phosphodeisterase -4 Inhibitor N-Cyclopropyl-1- -3{3-[(1-Oxidopyryidin-3-Yl) Phenyl]-4-Oxo-1,4-Dihydro-1,8-Naphthyridine-3-Carboxyamide | MERCK CANADA INC. (CA) | 2008-05-22 | — | — | US | disclosed |
| US-7312334-B2 | Method of preparing inhibitors phosphodiesterase-4 | MERCK & CO. INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7238706-B2 | 4-oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROSST CANADA, LTD. (CA) | 2007-07-03 | — | — | US | disclosed |
| US-20060258668-A1 | Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders | MERCK & CO., INC. | 2006-11-16 | — | — | US | disclosed |
| US-6909002-B2 | Method of preparing inhibitors of phosphodiesterase-4 | MERCK & CO., INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050107402-A1 | 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK CANADA INC. (CA) | 2005-05-19 | — | — | US | disclosed |
| US-6743802-B2 | ASTHMA THERAPY; ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA & CO. (CA) | 2004-06-01 | — | — | US | disclosed |
| US-20040102472-A1 | Method of preparing inhibitors of phosphodiesterase-4 | MERCK & CO., INC. | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102472-A1 | Method of preparing inhibitors of phosphodiesterase-4 | PDE4B, PDE4A, PDE5A | DHODH 141/4885MAPT 4803/4885MAPK1 2599/4885 |
| US-20080119509-A1 | Altenrative Forms Of The Phosphodeisterase -4 Inhibitor N-Cyclopropyl-1- -3{3-[(1-Oxidopyryidin-3-Yl) Phenyl]-4-Oxo-1,4-Dihydro-1,8-Naphthyridine-3-Carboxyamide | TPI1, ENPP1, SMPD4 | DHODH 154/4885MAPT 2770/4885MAPK1 3098/4885 |
| US-20060258668-A1 | Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders | PPP3CA, PTPA, PPP3CB | DHODH 987/4885MAPT 2114/4885MAPK1 1940/4885 |
| US-20050107402-A1 | 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE12 | DHODH 73/4885MAPT 2478/4885MAPK1 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.